MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling

Programmed death ligand 1 (PD‐L1) plays a significant role in colorectal tumorigenesis through induction of regulatory T cells (Tregs) and suppression of antitumor immunity. Furthermore, microRNAs (miRNAs) as the posttranscriptional regulators of gene expression show considerable promise as a therap...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2021-10, Vol.236 (10), p.7071-7087
Main Authors: Roshani Asl, Elmira, Rasmi, Yousef, Baradaran, Behzad
Format: Article
Language:English
Subjects:
3' Untranslated regions
Anticancer properties
Antitumor activity
Apoptosis
Cancer
CD44 antigen
Cell cycle
Cell differentiation
Cell migration
Cell proliferation
Cell surface
Colorectal cancer
Colorectal carcinoma
Functional analysis
G1 phase
Gene expression
Growth factors
Immunoregulation
Interferon
Interleukins
Lymphocytes
Lymphocytes T
MicroRNAs
miRNA
miRNA‐124
Myc protein
PD-L1 protein
PD‐L1
Post-transcription
Signaling
STAT3
Stat3 protein
Therapeutic targets
Transfection
Transforming growth factor-b
Tumor necrosis factor-α
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Programmed death ligand 1 (PD‐L1) plays a significant role in colorectal tumorigenesis through induction of regulatory T cells (Tregs) and suppression of antitumor immunity. Furthermore, microRNAs (miRNAs) as the posttranscriptional regulators of gene expression show considerable promise as a therapeutic target for colorectal cancer (CRC) treatment. Considering this, in vitro effects of miRNA‐124 (miR‐124‐3p) on CRC cell tumorigenesis and Tregs differentiation via targeting PD‐L1 were investigated in the current study. Functional analysis showed that miR‐124 is significantly downregulated in CRC tissues as compared with marginal normal samples (p 
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.30378